6月16日，晶泰控股盘中下跌5.18%，报6.59港元/股，成交额2.55亿港元。
消息面上，公司此前公布超4亿美元AI药物发现战略合作及1亿美元股份回购计划，但市场反应持续冷淡。尽管公司营收同比增长超200%并首次实现年度盈利，动态市盈率仍高达212倍，高估值回归压力持续主导股价走势。同时，港股通持股比例逼近50%买入上限，做空比例维持高位，资金结构矛盾加剧市场对利好催化的反应钝化。板块方面，生命科学工具和服务行业整体承压，药明康德跌1.68%，药明生物跌3.23%，金斯瑞生物科技跌4.07%，药明合联跌4.22%，英矽智能跌4.98%。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.